drugset / Trial / NCT01247168

An Open-Label, Dose-Escalation Study of AZD2461

NCT01247168 ↗

Phase 1 Completed 75 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to test study drug AZD2461 to see how it may work to treat solid tumors. The main purpose of this study is to determine the safety and tolerability of AZD2461. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.

Timeline

Start
2010-11
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2461 Small molecule — Oral

Indications